These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 8877552)

  • 1. The activity of cefetamet against enterobacterial isolates from community-acquired urinary tract infections.
    Sofianou D; Tsakris A; Nikolaidis P; Kotis E; Tourkantonis A
    J Antimicrob Chemother; 1996 Aug; 38(2):320-2. PubMed ID: 8877552
    [No Abstract]   [Full Text] [Related]  

  • 2. Urinary tract infection caused by fluoroquinolone- and cephem-resistant Enterobacteriaceae.
    Muratani T; Matsumoto T
    Int J Antimicrob Agents; 2006 Aug; 28 Suppl 1():S10-3. PubMed ID: 16829056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefetamet pivoxil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
    Bryson HM; Brogden RN
    Drugs; 1993 Apr; 45(4):589-621. PubMed ID: 7684677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro activity of cefetamet against enterobacteria expressing an SHV-5-type beta-lactamase.
    Tzouvelekis LS; Prinarakis EE; Gazouli M; Miriagou V; Tzelepi E; Legakis NJ
    Chemotherapy; 1996; 42(5):324-8. PubMed ID: 8874970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae isolates recovered from hospitalized patients in Germany.
    Seifert H; Körber-Irrgang B; Kresken M;
    Int J Antimicrob Agents; 2018 Feb; 51(2):227-234. PubMed ID: 28705666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
    Gesser RM; McCarroll K; Teppler H; Woods GL
    J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antimicrobial resistance among uropathogens that cause community-acquired urinary tract infections in Bangui, Central African Republic.
    Hima-Lerible H; Ménard D; Talarmin A
    J Antimicrob Chemother; 2003 Jan; 51(1):192-4. PubMed ID: 12493816
    [No Abstract]   [Full Text] [Related]  

  • 8. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
    Hallgren H; Gustafsson I; Ripa T
    Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
    [No Abstract]   [Full Text] [Related]  

  • 9. [Antimicrobial activities of cefetamet against clinical isolates from urinary tract infection].
    Ishii Y; Suzuki Y; Ishihara R; Nakazawa A; Deguchi K
    Jpn J Antibiot; 1996 Dec; 49(12):1073-84. PubMed ID: 9032594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ceftizoxime in the treatment of urinary tract infections.
    Plimpton HW; Crawford ED
    J Urol; 1982 Dec; 128(6):1231-2. PubMed ID: 6296465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cephalosporins in the treatment of urinary tract infections].
    Ukhin AV
    Antibiot Khimioter; 1990 Aug; 35(8):43-5. PubMed ID: 2264755
    [No Abstract]   [Full Text] [Related]  

  • 12. [A randomized controlled clinical study of cefetamet pivoxil versus cefixime in the treatment of 99 cases bacterial infections].
    Zhao C; Li J; Hao F
    Zhonghua Nei Ke Za Zhi; 1997 Jul; 36(7):465-8. PubMed ID: 10436948
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of cefpodoxime against staphylococci in comparison to other cephalosporins.
    Schumacher-Perdreau F; Jansen B; Peters G
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):585-8. PubMed ID: 1915402
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative in vitro activity of cefetamet (RO 15-8074).
    Machka K; Braveny I
    Eur J Clin Microbiol; 1987 Aug; 6(4):496-7. PubMed ID: 3478193
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative in vitro activity of cefditoren and other antimicrobials against Enterobacteriaceae causing community-acquired uncomplicated urinary tract infections in women: a Spanish nationwide multicenter study.
    Cuevas O; Cercenado E; Gimeno M; Marín M; Coronel P; Bouza E;
    Diagn Microbiol Infect Dis; 2010 Jul; 67(3):251-60. PubMed ID: 20542206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and bacteriological effects of cefetamet pivoxil against community-acquired respiratory tract infections. Part II].
    Shimada J; Ishihara R; Suzuki Y; Ishii Y; Nakazawa A; Deguchi K
    Jpn J Antibiot; 1997 Sep; 50(9):756-67. PubMed ID: 9394236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic effects of cefpirome (HR 810) on experimental mixed infections with Enterococcus faecalis and Escherichia coli in mice.
    Arai S; Hayashi S
    Infection; 1990; 18(3):186-90. PubMed ID: 2194972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cefepime versus carbapenems for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing enterobacteriaceae.
    Kim SA; Altshuler J; Paris D; Fedorenko M
    Int J Antimicrob Agents; 2018 Jan; 51(1):155-158. PubMed ID: 28943367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibacterial activity of cefpodoxime in vitro.
    Liu YC; Huang WK; Cheng DL
    Chemotherapy; 1997; 43(1):21-6. PubMed ID: 8996737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cefetamet pivoxil a new oral cephalosporin: clinical evaluation.
    Kissling M; Germano G; Fernex M
    Chemotherapy; 1988; 34(6):519-29. PubMed ID: 3243094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.